SOPHiA GENETICS (SOPH) CMO tax-related sale of 608 shares under 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported a small open-market sale of 608 ordinary shares of SOPH. The shares were sold at a weighted average price of $5.2002 per share and were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.

These transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Menu directly holds 266,388 ordinary shares, indicating that the transaction affected only a very small portion of his overall position.

Insights

Equity compensation and insider-trading specialist

Small, pre-planned sale mainly for taxes; minimal signal on SOPH.

The transaction involves the sale of 608 ordinary shares by Chief Medical Officer Philippe Menu at a weighted average price of $5.2002 per share. Footnotes state these sales were to cover tax withholding obligations from vesting restricted stock units on April 18, 2026.

The filing also discloses that the sales were executed under a pre-established Rule 10b5-1(c) trading plan, meaning the timing was pre-arranged rather than discretionary. After the sale, Menu still directly owns 266,388 ordinary shares, so this is a routine, small-scale disposition tied to equity compensation rather than a strong directional view on the stock.

Insider Trade Summary 10b5-1

Net Seller: 608 shares ($3,162)

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 608 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	608	$5.2002	$3K

Holdings After Transaction: Ordinary Shares — 266,388 shares (Direct, null)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.10 to $5.29, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 608 shares Weighted average sale price: $5.2002 per share Post-transaction holdings: 266,388 shares +3 more

6 metrics

Shares sold 608 shares Open-market sale on April 20, 2026

Weighted average sale price $5.2002 per share Ordinary shares sold in multiple transactions

Post-transaction holdings 266,388 shares Ordinary shares directly owned after sale

Sale price range $5.10–$5.29 per share Range of individual trade prices in the sale

Vesting date of RSUs April 18, 2026 Tax withholding obligations triggered on this date

Net share direction 608 net shares sold Net-sell direction from transaction summary

Key Terms

restricted stock units, tax withholding obligations, Rule 10b5-1(c) trading plan, weighted average price, +1 more

5 terms

restricted stock units financial

"arising in connection with the vesting of restricted stock units on April 18, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold ... to satisfy tax withholding obligations arising in connection with the vesting"

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market financial

"shares sold by the Reporting Person in the open market to satisfy tax withholding obligations"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/20/2026		S		608(1)	D	$5.2002(2)	266,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.10 to $5.29, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) Chief Medical Officer sell in this Form 4 filing?

The Chief Medical Officer, Philippe Menu, sold 608 ordinary shares of SOPHiA GENETICS. The sale was reported as an open-market transaction at a weighted average price of $5.2002 per share and was linked to the vesting of restricted stock units.

Why did Philippe Menu sell SOPH shares according to the Form 4?

The shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units on April 18, 2026. This means the transaction was primarily a tax-related event rather than a discretionary portfolio decision about SOPHiA GENETICS stock.

Was the SOPH share sale by Philippe Menu discretionary or pre-planned?

The sale was not discretionary. Footnotes state it was conducted under a pre-established Rule 10b5-1(c) trading plan. Such plans schedule trades in advance, reducing the significance of the transaction’s timing as an indicator of insider sentiment toward SOPHiA GENETICS.

How many SOPHiA GENETICS (SOPH) shares does Philippe Menu hold after this transaction?

After selling 608 ordinary shares, Philippe Menu holds 266,388 ordinary shares directly. This indicates that the reported sale represents only a very small fraction of his total holdings and appears as a routine adjustment tied to equity compensation.

At what prices were the SOPH shares sold in Philippe Menu’s Form 4?

The reported price of $5.2002 per share is a weighted average. Footnotes explain the 608 shares were sold in multiple transactions, with individual prices ranging from $5.10 to $5.29 per share, all within that disclosed price range.

Does this SOPH Form 4 filing indicate any remaining options or derivatives for Philippe Menu?

The derivative section of the filing is empty, and no remaining options or other derivatives are listed for Philippe Menu. The Form 4 focuses on the sale of ordinary shares connected to restricted stock unit vesting and related tax withholding obligations.